L. Hester

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
L. Hester, Laura Hester, Laura L. Hester, Laura L Hester
Publication record
23 papers · 458 citations · H-index 8

PAPERS

Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data
20231 citationsauthor #2
Epidemiology and clinical outcomes of light‐chain amyloidosis in Sweden: A nationwide population‐based study
20237 citationsauthor #3
POSTER: MM-344 Real-World Patient Profile and Step-up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma (MM) in a Hospital Setting in the US: Premier Healthcare Database Study
20231 citationsauthor #4
Light-Chain Amyloidosis in Sweden (2011-2019): Incidence, Disease Burden, and Clinical Outcomes in Real-World Patients
20223 citationsauthor #3
Update on prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016
20220 citationsauthor #2
Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain
202112 citationsauthor #23
Characteristics and outcomes of 118,155 COVID-19 individuals with a history of cancer in the United States and Spain
20210 citationsauthor #23
Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019
202138 citationsauthor #1
Update on prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016
20213 citationsauthor #2
Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
2020139 citationsauthor #20
Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study
20205 citationsauthor #4
DIAGNOSTIC DELAY AND CHARACTERIZATION OF THE CLINICAL PRODROME IN AL AMYLOIDOSIS RELATED CARDIOMYOPATHY AMONG 1,173 PATIENTS DIAGNOSED BETWEEN 2001-2018
20201 citationsauthor #1
Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study
202025 citationsauthor #16
Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study
2020120 citationsauthor #21
Risk of depression, suicidal ideation, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multi-national network cohort study
20203 citationsauthor #16
Diagnostic Delay and Characterization of the Clinical Prodrome in AL Amyloidosis: Data from 1,313 US Commercially Insured Patients between 2006-2018
20192 citationsauthor #1
1546-P: Acute Pancreatitis (AP) with Canagliflozin (CANA) vs. Other Antihyperglycemic Agents (AHAs): An Observational Study
20190 citationsauthor #4
Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases
201942 citationsauthor #4
Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients
201915 citationsauthor #6
Abstract 24: Diabetic Ketoacidosis in Patients with Type 2 Diabetes Treated with Sodium Glucose Co-transporter 2 Inhibitors versus Other Antihyperglycemic Agents: An Observational Study of Four US Administrative Claims Databases
20190 citationsauthor #4
Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma
20170 citationsauthor #1
Publication of comparative effectiveness research has not increased in high-impact medical journals, 2004-2013.
20173 citationsauthor #1
Methodologic Issues when Estimating Risks in Pharmacoepidemiology
201640 citationsauthor #2

TIMELINE

2016 40 citations

2017 3 citations

2019 59 citations

2020 293 citations

2021 53 citations

2022 3 citations

2023 9 citations

L. Hester

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT